Journal of Pharmaceutical and Biomedical Analysis Letters
ISSN: 2347-4742 | https://doi.org/10.30904/j.jpbmal.2026.4949
J. Pharm, Biomed. A. Lett., 2026; 14(2): 25-27

Phytoconstituents as Potential Anticancer Agents: Mechanisms, Evidence, and Therapeutic Prospects

SK. Salma Sultana[1]*, R. Swarupa Rani[2], D. Venkata Harsha Vardan[2], P. Likitha[2], Damai Ashok[2]

[1]Professor, Department of Pharmacology, Narayana Pharmacy College, Nellore
[2]B.Pharmacy student, Narayana Pharmacy College, Nellore

***Corresponding E-mail:** salmasulthanacology@gmail.com*

Keywords
Phytoconstituents;
Cancer therapy;
Apoptosis;
Resveratrol
Natural products

Received 29-01-2026
Revised 16-02-2026
Accepted 25-03-2026
Published 25-05-2026

ABSTRACT
Cancer remains a major global health challenge despite advances in diagnosis and treatment. Conventional therapies such as chemotherapy and radiotherapy are often limited by systemic toxicity, resistance development, and damage to healthy tissues. Phytoconstituents, bioactive secondary metabolites derived from medicinal plants, have gained considerable attention as potential anticancer agents due to their multi-targeted mechanisms, relative safety, and chemopreventive properties. This study reviews the classification, molecular mechanisms, experimental evidence, clinical relevance, advantages, and limitations of phytoconstituents in cancer therapy. Evidence from in vitro, in vivo, and clinical studies indicates that compounds such as curcumin, resveratrol, epigallocatechin gallate (EGCG), genistein, sulforaphane, silymarin, vincristine, vinblastine, and paclitaxel modulate key signaling pathways including NF-κB, PI3K/Akt, MAPK, p53, VEGF, and STAT3. These compounds exert anticancer effects through apoptosis induction, cell cycle arrest, inhibition of angiogenesis, suppression of metastasis, epigenetic modulation, and targeting of cancer stem cells. Although limitations such as poor bioavailability and insufficient large-scale clinical validation persist, advancements in nanotechnology and targeted drug delivery systems offer promising solutions. Phytoconstituents represent a valuable bridge between traditional medicine and modern oncology and may contribute significantly to future cancer prevention and therapy strategies.

INTRODUCTION

Cancer is characterized by uncontrolled cellular proliferation, resistance to apoptosis, angiogenesis, invasion, and metastasis. Although synthetic chemotherapeutic agents have improved survival rates, their clinical use is frequently associated with toxicity, drug resistance, and limited specificity.

Therefore, there is a growing interest in identifying safer and multi-targeted therapeutic agents. Phytoconstituents are naturally occurring bioactive compounds derived from plants. These compounds are primarily secondary metabolites, which play protective roles in plants and possess diverse pharmacological activities in humans. Historically, plant-derived compounds have contributed significantly to modern pharmacotherapy. Notably, vincristine and vinblastine from *Catharanthus roseus*, and paclitaxel from *Taxus brevifolia*, are well-established anticancer drugs.

Recent research has expanded focus toward dietary and medicinal phytochemicals such as curcumin, resveratrol, genistein, EGCG, sulforaphane, and silymarin, which exhibit anticancer properties by modulating molecular signaling pathways. This study aims to comprehensively analyze the mechanisms and therapeutic potential of phytoconstituents in cancer management.

MATERIALS AND METHODS

This study was conducted as a structured narrative review of published literature including peer-reviewed research articles, clinical trials, systematic reviews, and pharmacological databases. Sources were selected based on relevance to phytoconstituents with demonstrated anticancer mechanisms. Emphasis was placed on molecular mechanisms, preclinical models, clinical evidence, and formulation advancements.
Data were categorized under:

- Classification of phytoconstituents
- Molecular mechanisms of anticancer action
- Experimental and clinical evidence
- Advantages and limitations
- Emerging therapeutic strategies

RESULTS

3.1 Classification of Anticancer Phytoconstituents

Phytoconstituents with anticancer activity are broadly categorized as:

- **Alkaloids**: Vincristine, vinblastine, berberine
- **Flavonoids**: Quercetin, EGCG, kaempferol
- **Terpenoids**: Paclitaxel, artemisinin
- **Phenolic compounds**: Curcumin, resveratrol
- **Saponins**: Ginsenosides, dioscin

- **Lignans**: Podophyllotoxin
- **Carotenoids**: Lycopene, β-carotene

Among these, alkaloids and terpenoids have progressed into clinically approved chemotherapeutic agents.

3.2 Molecular Mechanisms of Anticancer Action

3.2.1 Induction of Apoptosis

Multiple phytoconstituents restore programmed cell death by:

- Activating caspase pathways
- Upregulating pro-apoptotic proteins (Bax, Bak)
- Downregulating anti-apoptotic proteins (Bcl-2)

Curcumin, resveratrol, and genistein demonstrated significant apoptosis induction in breast and colon cancer cell lines.

3.2.2 Cell Cycle Arrest: EGCG and quercetin have been shown to arrest cancer cells in G0/G1 or G2/M phases by regulating cyclins and cyclin-dependent kinases (CDKs), thereby inhibiting uncontrolled proliferation.

3.2.3 Inhibition of Angiogenesis

Resveratrol and genistein suppressed VEGF-mediated angiogenesis in experimental tumor models, reducing tumor vascularization and nutrient supply.

3.2.4 Suppression of Metastasis

Silymarin and apigenin inhibited matrix metalloproteinases (MMPs), reducing invasion and metastatic spread in preclinical studies.

3.2.5 Epigenetic Modulation

EGCG and genistein inhibited DNA methyltransferases and histone deacetylases, restoring normal gene expression patterns in cancer cells.

3.2.6 Targeting Cancer Stem Cells

Curcumin and sulforaphane demonstrated inhibitory effects on Wnt, Notch, and Hedgehog signaling pathways associated with cancer stem cell survival and recurrence.

3.3 Evidence from Experimental and Clinical Studies

- Curcumin reduced tumor growth in animal models and demonstrated suppression of NF-κB and STAT3 signaling.
- Resveratrol induced apoptosis and reduced tumor incidence in murine models.
- EGCG inhibited EGFR and VEGF signaling and was associated with reduced recurrence in prostate cancer patients.
- Sulforaphane enhanced phase II detoxifying enzymes and promoted apoptosis in colon cancer cells.
- Paclitaxel and vincristine remain frontline chemotherapeutic agents due to their microtubule-targeting mechanisms.

Collectively, experimental findings consistently demonstrate multi-pathway modulation by phytoconstituents, supporting their therapeutic relevance.

Table.1: Results Summary Table

Compound	Class	Primary Mechanism	Target Pathways
Curcumin	Phenolic	Apoptosis, Anti-inflammatory	NF-κB, STAT3, COX-2
Resveratrol	Polyphenol	Cell cycle arrest, Anti-angiogenic	VEGF, PI3K/Akt
EGCG	Flavonoid	G1 Arrest, Anti-angiogenic	EGFR, VEGF
Paclitaxel	Terpenoid	Microtubule stabilization	Mitotic arrest
Vincristine	Alkaloid	Microtubule inhibition	Tubulin polymerization





Discussion

Phytoconstituents exhibit significant anticancer potential through multi-targeted mechanisms. Unlike single-target synthetic drugs, these compounds modulate interconnected signaling networks including NF-κB, PI3K/Akt, MAPK, p53, and VEGF pathways. Their chemopreventive properties also contribute to reduced carcinogenesis by minimizing oxidative stress and chronic inflammation. Importantly, synergy with conventional chemotherapeutics enhances tumor sensitivity while potentially reducing systemic toxicity.

However, several limitations hinder clinical translation:

Poor bioavailability (e.g., curcumin, resveratrol)

- Rapid metabolism and degradation
- Lack of large-scale randomized clinical trials
- Variability in natural sources
- Drug–herb interactions

Emerging solutions include nanoparticle delivery systems, liposomal formulations, phytosomes, and conjugate-based targeting systems to enhance solubility, stability, and tumor specificity.

5. Advantages and Limitations

Advantages

- Multi-targeted mechanisms
- Lower systemic toxicity
- Chemopreventive potential
- Synergistic with chemotherapy
- Reduced resistance development

Limitations

- Low bioavailability
- Standardization challenges
- Limited clinical validation
- Stability issues
- Regulatory concerns

6. Future Perspectives

Future research should focus on:

- Clinical validation through randomized controlled trials
- Personalized phytochemical-based therapy
- Nanotechnology-based delivery platforms
- Combination therapy optimization
- Molecular biomarker identification
- Cancer stem cell-targeted phytochemicals

CONCLUSION

Phytoconstituents represent a promising and scientifically validated class of anticancer agents. Their ability to modulate multiple molecular pathways aligns well with the multifactorial nature of cancer. While certain plant-derived compounds have already achieved clinical success, many others remain under investigation. Overcoming challenges related to bioavailability and clinical validation will be essential for their broader integration into modern oncology. Continued translational research may enable phytoconstituents to play a central role in safer, more effective, and holistic cancer therapy strategies.

ACKNOWLEDGMENT

The authors thank the, Narayana Pharmacy College, Nellore, Andhra Pradesh, India, for technical assistance and support.

CONFLICT OF INTERESTS

The authors declare no conflict of interest

ETHICS APPROVAL

Not applicable

FUNDING

This study received no specific funding from public, commercial, or not for profit funding agencies.

AI TOOL DECLARATION

The authors declare that no AI and related tools are used to write the scientific content of this manuscript.

DATA AVAILABILITY

Data will be available on request

REFERENCES

[1] Cragg GM, Pezzuto JM. Natural products as a source of anticancer agents. J Nat Prod. 2016;79(3):629–661.

[2] Choudhari AS, Mandave PC, Deshpande M, et al. Phytochemicals in cancer treatment. Front Pharmacol. 2020; 11: 593.

[3] Zhang Y,. Anticancer activities of phytoconstituents. Pharmaceutics. 2020; 12: 123.

[4] Nakonieczna J, et al. Anticancer activity of phytochemicals in gastric cancer. Cancers. 2020; 12:789.

[5] Salma sultana Sk, Banurekha J, Kumar M. Screening of anti colon cancer activity by using hydro alcoholic extract of Borassus Fabilifers hoot on swiss albino mice. Asian journal of Pharmaceutical and Clinical Research. 2025:18(7): 129-134.

[6] Rudzińska M, et al. Phytochemicals in cancer therapy. Int J Mol Sci. 2023; 24:4567.